

Crystallographic study of the phosphoethanolamine transferase EptC required for polymyxin resistance and motility in *Campylobacter jejuni*

Christopher D. Fage,^{a‡} Dusty B. Brown,^{b‡} Joseph M. Boll,^b Adrian T. Keatinge-Clay^{a*} and M. Stephen Trent^{b*}

^aMolecular Biosciences, University of Texas at Austin, 1 University Station, Stop A5300, Austin, TX 78712, USA, and ^bMolecular Biosciences, University of Texas at Austin, 2506 Speedway, Stop A5000, Austin, TX 78613, USA

‡ These authors contributed equally to the preparation of this manuscript.

Correspondence e-mail: adriankc@utexas.edu, strent@mail.utexas.edu

The foodborne enteric pathogen *Campylobacter jejuni* decorates a variety of its cell-surface structures with phosphoethanolamine (pEtN). Modifying lipid A with pEtN promotes cationic antimicrobial peptide resistance, whereas post-translationally modifying the flagellar rod protein FlgG with pEtN promotes flagellar assembly and motility, which are processes that are important for intestinal colonization. EptC, the pEtN transferase required for all known pEtN cell-surface modifications in *C. jejuni*, is a predicted inner-membrane metalloenzyme with a five-helix N-terminal transmembrane domain followed by a soluble sulfatase-like catalytic domain in the periplasm. The atomic structure of the catalytic domain of EptC (cEptC) was crystallized and solved to a resolution of 2.40 Å. cEptC adopts the $\alpha/\beta/\alpha$ fold of the sulfatase protein family and harbors a zinc-binding site. A phosphorylated Thr266 residue was observed that was hypothesized to mimic a covalent pEtN–enzyme intermediate. The requirement for Thr266 as well as the nearby residues Asn308, Ser309, His358 and His440 was ascertained *via in vivo* activity assays on mutant strains. The results establish a basis for the design of pEtN transferase inhibitors.

Received 10 February 2014

Accepted 31 July 2014

PDB reference: EptC, 4tn0

1. Introduction

Bacteria maintain a complex outer surface that gives rise to a variety of biological functions. *O*-Linked phospho-form modifications such as phosphoethanolamine (pEtN), phosphoglycerol and phosphocholine are found on a variety of surface molecules, where they promote biosynthesis and pathogenic functions in certain organisms. For example, pEtN modifications are commonly associated with lipopolysaccharide/lipooligosaccharide (LPS/LOS) in Gram-negative bacteria and have dedicated roles in the recognition and evasion of host innate immune responses (Raetz *et al.*, 2007; Trent *et al.*, 2006; Needham & Trent, 2013). More recently, post-translational phospho-form modifications of the type IV pili subunits of pathogenic *Neisseria* species and the flagellar rod protein FlgG of *Campylobacter jejuni* have extended these modifications to cell-surface proteins (Cullen & Trent, 2010; Chamot-Rooke *et al.*, 2011; Naessan *et al.*, 2008).

Our laboratory previously identified the EptC protein, a unique pEtN transferase in *C. jejuni* (Cullen & Trent, 2010). *C. jejuni* is a Gram-negative enteric pathogen responsible, in large part, for foodborne illness and bacteria-associated diarrhea in the United States and abroad (Scallan *et al.*, 2011; Havelaar *et al.*, 2013). In terms of burden to health and cost, campylobacteriosis ranks highest among foodborne infections (Batz *et al.*, 2012). Contracted by ingestion of contaminated poultry and beef products, the disease is characterized by

gastrointestinal colonization followed by acute diarrhea. In rare instances, secondary neurological symptoms may persist in the form of the debilitating autoimmune disease Guillain-Barré syndrome (Yuki & Hartung, 2012; Israeli *et al.*, 2012).

C. jejuni has evolved a single pEtN transferase, EptC, that modifies an array of cell-surface molecules, including the 1- and 4'-phosphoryl groups of lipid A (Cullen & Trent, 2010), the first heptose residue of the inner-core oligosaccharide of LOS (Cullen *et al.*, 2013), residue Thr75 of the flagellar rod protein FlgG (Cullen *et al.*, 2012) and the N-linked glycans of numerous glycoproteins (Scott *et al.*, 2012) (Fig. 1). Conversely, most mucosal pathogens appear to express several pEtN transferases dedicated to the modification of one specific target. For example, pathogenic *Neisseria* species produce the

enzymes LptA, Lpt3, Lpt6 and PptA that specifically transfer pEtN to only one of the following: lipid A phosphoryl groups (Cox *et al.*, 2003), position 3 of LOS core heptose II (MacKinnon *et al.*, 2002; Wenzel *et al.*, 2010), position 6 of LOS core heptose II (Wright *et al.*, 2004) or the major pilin protein PilE (Naessan *et al.*, 2008), respectively. Likewise, *Escherichia coli* species possess at least three functional pEtN transferases (EptA, EptB and CptA) that attach pEtN groups to specific positions of LPS (Raetz *et al.*, 2007). Owing to its uniquely promiscuous nature, EptC is linked to multiple and distinct biological functions in *C. jejuni*. Mutational studies demonstrate that the loss of pEtN modifications causes a drastic reduction in flagellar assembly/motility and a significantly higher sensitivity to a range of cationic antimicrobial peptides (Cullen & Trent, 2010; Cullen *et al.*, 2012). Most importantly, EptC expression is required for proper intestinal colonization of *C. jejuni* in avian and mouse infection models (Cullen *et al.*, 2013).

The *eptC* gene (locus tag Cj0256) is clustered in a family of inner-membrane metalloenzymes (COG2194) containing a five-helix transmembrane domain and a periplasmic catalytic domain that is currently grouped in the sulfatase family (Pfam00884; Marchler-Bauer *et al.*, 2013; Fig. 1). Placement of the catalytic domain dictates that pEtN modification occurs on the periplasmic side of the inner membrane, where EptC transfers head groups from the phospholipid phosphatidylethanolamine to target molecules. Indeed, EptC activity is not observed when the enzyme is heterologously expressed in a phosphatidylethanolamine-deficient *E. coli* strain (Cullen & Trent, 2010). To gain insight into the structural basis of enzyme function, we crystallized and determined the atomic coordinates of the catalytic domain of EptC (cEptC) to a resolution of 2.40 Å. Our structural data along with mutational analysis of EptC allowed us to identify zinc-ligand residues, a putative nucleophile and conserved active-site residues required for *in vivo* activity. Moreover, we juxtaposed the structures of cEptC and the catalytic domains of the related enzymes cLtaS (lipoteichoic acid




Figure 1

Topology and biological functions of the *C. jejuni* phosphoethanolamine transferase EptC. (a) EptC is predicted to be anchored to the inner membrane by a five-helix transmembrane domain, with its sulfatase-like catalytic domain positioned in the periplasm. EptC transfers pEtN (red circles) from the head groups of phosphatidylethanolamine onto the LOS core (gray rectangles) and phosphates (white circles) of lipid A and Thr75 of FlgG proteins (blue boxes). Modifications of these *C. jejuni* surface structures with pEtN promote flagellar assembly, motility, cationic antimicrobial peptide resistance and host intestinal colonization (Cullen & Trent, 2010; Cullen *et al.*, 2012, 2013). The organization of flagellar components has previously been proposed (Chevance & Hughes, 2008). (b) Chemical structures of *C. jejuni* LOS and phosphatidylethanolamine, with pEtN moieties in red. R_1 , β -D-glucose; R_2 , outer core sugars; pEtN, phosphoethanolamine; PtdEtN, phosphatidylethanolamine; DAG, diacylglycerol; LOS, lipooligosaccharide.

Table 1
Bacterial strains and plasmids.

Strains and plasmids	Description	Source
<i>Escherichia coli</i>		
XL1-Blue	General cloning strain, <i>recA1 endA1 gyrA96thi-1 hsdR17</i>	Stratagene
BL21(DE3)	Protein-expression strain, F ⁻ <i>ompT gal dcm lon hsdS_B(r_B⁻ m_B⁻) λ(DE3)</i>	Novagen
<i>Campylobacter jejuni</i>		
81-176	Serotype HS: 23, 26	Cullen & Trent (2010)
81-176 A1	81-176 Δ <i>cj0256</i> clone1, Cam ^R	Cullen & Trent (2010)
81-176 B	Complement strain, 81-176 Δ <i>cj0256</i> Δ <i>astA::cj0256</i> , Cam ^R , Kan ^R	Cullen & Trent (2010)
81-176 <i>eptC</i> _{T266A}	81-176 Δ <i>cj0256</i> Δ <i>astA::cj0256</i> _{T266A} , Cam ^R , Kan ^R	This study
81-176 <i>eptC</i> _{T266S}	81-176 Δ <i>cj0256</i> Δ <i>astA::cj0256</i> _{T266S} , Cam ^R , Kan ^R	This study
81-176 <i>eptC</i> _{N308A}	81-176 Δ <i>cj0256</i> Δ <i>astA::cj0256</i> _{N308A} , Cam ^R , Kan ^R	This study
81-176 <i>eptC</i> _{S309A}	81-176 Δ <i>cj0256</i> Δ <i>astA::cj0256</i> _{S309A} , Cam ^R , Kan ^R	This study
81-176 <i>eptC</i> _{H358A}	81-176 Δ <i>cj0256</i> Δ <i>astA::cj0256</i> _{H358A} , Cam ^R , Kan ^R	This study
81-176 <i>eptC</i> _{H440A}	81-176 Δ <i>cj0256</i> Δ <i>astA::cj0256</i> _{H440A} , Cam ^R , Kan ^R	This study
Plasmids		
pET-28b(+)	Expression vector containing a T7 promoter, Amp ^R	Novagen
pETcEptC	pET-28b(+)-derived expression plasmid used to express cEptC, Amp ^R	This study
pAtsAKO:: <i>cj0256</i> :Kan ^R	pGEM-atsAKO:Kan ^R with <i>cj0256</i> inserted	Cullen & Trent (2010)
pETcEptC _{T266S}	T266S mutant derivative of pETcEptC, Amp ^R	This study
pAstAEptC _{T266A}	T266A mutant derivative of pAtsAKO:: <i>cj0256</i> :Kan ^R	This study
pAstAEptC _{T266S}	T266S mutant derivative of pAtsAKO:: <i>cj0256</i> :Kan ^R	This study
pAstAEptC _{N308A}	N308A mutant derivative of pAtsAKO:: <i>cj0256</i> :Kan ^R	This study
pAstAEptC _{S309A}	S309A mutant derivative of pAtsAKO:: <i>cj0256</i> :Kan ^R	This study
pAstAEptC _{H358A}	H358A mutant derivative of pAtsAKO:: <i>cj0256</i> :Kan ^R	This study
pAstAEptC _{H440A}	H440A mutant derivative of pAtsAKO:: <i>cj0256</i> :Kan ^R	This study

synthase from *Bacillus subtilis* and *Staphylococcus aureus*) and cLptA (lipid A pEtN transferase from *N. meningitidis*). The observed structural differences around the active sites of cEptC and the lipid A-specific cLptA may provide clues to the promiscuous nature of EptC.

2. Materials and methods

2.1. Strains and plasmid construction

The primers, plasmids and strains used in this study are listed in Tables 1 and 2. Plasmid pETcEptC was constructed for the overexpression of the catalytic domain of EptC (cEptC; residues 203–512) fused to a Gly₆His₈ tag at the C-terminus using the Polymerase Incomplete Primer Extension (PIPE) method (Klock & Lesley, 2009). Briefly, the plasmid pET-28b(+) (Novagen) was linearized using the V-PIPE primers 1 and 2 and subsequently gel-purified and treated with the restriction enzyme *DpnI* (New England Biolabs). The insert was colony PCR-amplified from *C. jejuni* 81-176 using the I-PIPE primers 3 and 4. The insert and linearized vector were mixed, transformed into XL1-Blue *E. coli* cells (Stratagene) and incubated overnight at 37°C on LB-agar plates containing 50 μg ml⁻¹ kanamycin.

EptC active-site mutants were constructed by site-directed mutagenesis of plasmid pAtsAKO::*cj0256*-Kan^R (Cullen *et al.*, 2012) using primers 5–16 (Tables 1 and 2). The mutant alleles were introduced into the *eptC* mutant strain *C. jejuni* 81-176 Δ*cj0256* as described previously (Cullen & Trent, 2010).

2.2. Expression, purification and crystallization of cEptC

E. coli BL21(DE3) cells expressing cEptC were cultured in LB with 50 mg l⁻¹ kanamycin at 37°C. Upon reaching an OD₆₀₀ of 0.6, the cultures were cooled to 18°C and induced

with 0.5 mM IPTG. After 18 h, the cells were pelleted, resuspended in lysis buffer [500 mM NaCl, 30 mM HEPES pH 7.5, 10% (v/v) glycerol] and sonicated. The lysate was clarified by centrifugation and the soluble portion was poured over an Ni-NTA column (Expedeon) equilibrated with lysis buffer. The beads were washed with 15 mM imidazole in lysis buffer and the bound protein was eluted with 150 mM imidazole in lysis buffer. The eluate was further purified on a Superdex 200 gel-filtration column (GE Healthcare Life Sciences) equilibrated with 150 mM NaCl, 10 mM HEPES pH 7.5. Selenomethionine (SeMet)-derivative protein was purified similarly but was expressed in minimal medium with 50 mg l⁻¹ kanamycin supplemented with amino acids for methionine-pathway inhibition (Doublé, 1997).

SeMet-derivative and native proteins were concentrated to 30 mg ml⁻¹ in 25 mM NaCl, 10 mM HEPES pH 7.5. Crystals were grown over the course of several days by sitting-drop vapor diffusion at 22°C by combining 4 μl protein solution with 1 μl 200 mM diammonium phosphate, 15% (w/v) PEG 3350. SeMet-derived protein crystallized in space group *P*₂₁₂₁, while the native protein crystallized in space group *C*22₁. Before flash-cooling in liquid nitrogen, the crystals were cryoprotected in 200 mM diammonium phosphate, 16.5% (w/v) PEG 3350, 10% (v/v) glycerol for 10 s.

2.3. X-ray diffraction data collection, processing, phasing and refinement

Native and SeMet-derivative data were collected on Advanced Photon Source beamline 23-ID-B and processed and scaled in *HKL*-2000 (Otwinowski & Minor, 1997) (Table 3). Reflection intensities were converted to amplitudes in *TRUNCATE* (French & Wilson, 1978) from the *CCP4* software suite (Winn *et al.*, 2011). A single-wavelength

anomalous dispersion (SAD) data set was collected at the Se *K* edge ($\lambda = 0.9795 \text{ \AA}$) from one SeMet-derived cEptC crystal that diffracted to 2.80 \AA resolution. Initial phases were obtained from *AutoSol* of the *PHENIX* software suite (Adams *et al.*, 2010), which identified 46 Se sites (30 were expected for six monomers based on the sequence; figure of merit = 0.329) in a $P2_12_12_1$ unit cell and generated six partial cEptC monomers in the asymmetric unit ($R_{\text{work}}/R_{\text{free}} = 32.9/37.8\%$; map–model correlation coefficient = 0.747). One of the six monomers was subjected to several cycles of refinement in *Coot* (Emsley & Cowtan, 2004) and *REFMAC5* (Murshudov *et al.*, 2011) from *CCP4* and was then employed as a molecular-replacement search model to phase the native data set in *Phaser* (McCoy *et al.*, 2007) from *CCP4*. One native cEptC crystal diffracted to 2.50 \AA resolution (Zn remote, $\lambda = 1.0332 \text{ \AA}$), with a $C222_1$ unit cell containing three monomers. Iterative refinement was carried out in *Coot* and *phenix.refine* of *PHENIX*, with default NCS restraints applied in the latter. Notably, for the $P2_12_12_1$ (SeMet-derivative) data set, *phenix.xtriage* from *PHENIX* identified an off-origin Patterson peak that was 30% of the origin peak, which strongly indicates the presence of translational pseudo-symmetry. No pseudo-symmetry was detected for the $C222_1$ (native) data set.

The X-ray fluorescence of native cEptC crystals was examined on Advanced Light Source beamline 4.2.2 to identify the catalytic metal ion. A data set was collected at the Zn *K* edge ($\lambda = 1.2680 \text{ \AA}$) from one crystal to 2.40 \AA resolution; this was processed in *XDS* (Kabsch, 2010) and scaled in *SCALA* (Evans, 2006) from *CCP4*. Data were truncated at a resolution at which a compromise was reached between the $\langle I/\sigma(I) \rangle$ and $CC_{1/2}$ values (Karplus & Diederichs, 2012; Diederichs & Karplus, 2013). Refinement was carried out as described above. The two native data sets were merged in *CAD* to generate an anomalous difference map in *FFT* (Read & Schierbeek, 1988; both programs are from *CCP4*). The Zn *K* edge data set was selected for deposition owing to less

Table 2
Primers used in this study.

Underlined regions indicate introduced mutations.

1. F-VPIPEcEptC	5'-ACCCCGCCTCCCCTGGATTGGCTTAAAGTTTAGGATTTAA-3'
2. R-VPIPEcEptC	5'-AGGAGATATACCATGTTTAAAACTATAGCTAATGATGCTTATA-3'
3. F-IPIPEcEptC	5'-GGGGAGGCGGGTGGACACCACCACCACCACCACCACCTGAGAT-3'
4. R-IPIPEcEptC	5'-CATGGTATATCTCCTTCTTAAAGTTAAACAAAATTATT-3'
5. F-EptCT266S	5'-ATTTTTCATCATGTGGAACAGCAAGCGCGGTAAGTTTGCCTTGTATGTTT-3'
6. R-EptCT266S	5'-AAACATACAAGGCAAACCTTACCGCGCTTGCTGTCCACATGATGAAAAAT-3'
7. F-EptCT266A	5'-ATTTTTCATCATGTGGAACAGCAGCGCGGTAAGTTTGCCTTGTATGTTT-3'
8. R-EptCT266A	5'-AAACATACAAGGCAAACCTTACCGCGCTTGCTGTCCACATGATGAAAAAT-3'
9. F-EptCN308A	5'-GCATGGTTTGATAATGCATCTGGTGGTTGTAATA-3'
10. R-EptCN308A	5'-TTTACAACCACAGATGCATTATCAAAACCATGC-3'
11. F-EptCS309A	5'-TGGTTTGATAATAATGCAGGTGGTTGTAAGGG-3'
12. R-EptCS309A	5'-CCCTTTACAACCACCTGCATTATTATCAAAACCA-3'
13. F-EptCH358A	5'-CATTGCAAGTCTGCAGGGCCAATTATTAT-3'
14. R-EptCH358A	5'-ATAATAAGTTGGCCCTCGAGAACCTTGCAAATG-3'
15. F-EptCH440A	5'-AATGGTATTTATCTTGCAGGTATGCCTTATGCT-3'
16. R-EptCH440A	5'-AGCATAAGGCATACCTCGAAGATAAATACCATT-3'




Figure 2
Structure of the C-terminal catalytic domain of the pEtN transferase EptC (cEptC) from *C. jejuni*. (a) Secondary-structural features of a monomer. α -Helices (green), β -strands (red) and loops (gray) are labeled as in Supplementary Fig. S3. Disulfides (yellow) and the phosphothreonine residue are displayed in ball-and-stick representation, Zn^{2+} (purple) is displayed as a sphere and the N- and C-termini are labeled. The dotted line indicates residues 213–215, for which there is no observable electron density in monomer A. (b) Zinc-binding residues of the phosphoenzyme intermediate. $2F_o - F_c$ map density (blue mesh) is contoured at 2.0 r.m.s.d. The metal ion was identified as Zn^{2+} by anomalous diffraction (see Supplementary Fig. S7). Coordination bonds between side chains and Zn^{2+} are indicated by dashed lines. All molecular images were generated in *PyMOL* (Schrödinger).

apparent radiation damage to disulfides and zinc ions, as evident in the $F_o - F_c$ density (Supplementary Fig. S1¹; Weik *et al.*, 2000; Burmeister, 2000). The structure-factor amplitudes and atomic coordinates of cEptC were deposited in the RCSB Protein Data Bank as PDB entry 4tn0.

2.4. Protein mass spectrometry

LC-MS (AB Sciex 4000 QTrap hybrid triple quadrupole-linear ion trap with Shimadzu Prominence analytical LC) was

¹ Supporting information has been deposited in the IUCr electronic archive (Reference: MH5132).

Table 3
Data-collection and refinement statistics for cEptC.

Values in parentheses are for the outer shell.

	Native, Zn <i>K</i> edge	Native, Zn remote wavelength	SeMet derivative, Se <i>K</i> edge
Data collection			
Space group	<i>C</i> 222 ₁	<i>C</i> 222 ₁	<i>P</i> 2 ₁ 2 ₁ 2 ₁
X-ray source	Advanced Light Source, 4.2.2	Advanced Photon Source, 23-ID-B	Advanced Photon Source, 23-ID-B
Wavelength (Å)	1.2680	1.0332	0.9795
Temperature (K)	100	100	100
Unit-cell parameters (Å, °)	<i>a</i> = 121.9, <i>b</i> = 183.1, <i>c</i> = 121.5, $\alpha = \beta = \gamma = 90.0$	<i>a</i> = 122.5, <i>b</i> = 183.6, <i>c</i> = 121.7, $\alpha = \beta = \gamma = 90.0$	<i>a</i> = 119.1, <i>b</i> = 120.8, <i>c</i> = 182.7, $\alpha = \beta = \gamma = 90.0$
Resolution (Å)	55–2.40 (2.46–2.40)	50–2.50 (2.54–2.50)	50–2.80 (2.85–2.80)
<i>R</i> _{merge} [†] (%)	11.2 (99.6)	11.9 (95.5)	12.1 (82.9)
CC _{1/2} [‡] (%)	99.6 (67.4)	99.0 (85.4)	99.8 (75.6)
Average <i>I</i> / σ (<i>I</i>)	10.6 (1.5)	18.2 (2.8)	14.3 (2.0)
No. of observed reflections	392584	349675	729109
No. of unique reflections	53319 (3892)	47144 (2327)	119456 (5831)
Oscillation step (°)	0.2	1.0	1.0
No. of images	900	180	360
Exposure time per image (s)	0.4	1.0	1.0
Completeness (%)	99.7 (99.6)	99.9 (100)	99.7 (97.6)
Multiplicity	7.4 (7.4)	7.4 (7.2)	6.1 (4.9)
Monomers in asymmetric unit	3	3	6
Solvent content (%)	61.8	60.6	59.0
Matthews coefficient (Å ³ Da ⁻¹)	3.22	3.12	3.00
Refinement			
Resolution (Å)	54.58–2.40 (2.43–2.40)		
<i>R</i> _{work} / <i>R</i> _{free} [§] (%)	21.5/25.6 (33.0/38.8)		
No. of atoms			
Overall	7411		
Protein	7378		
Ligand¶	15		
Water	18		
Average <i>B</i> factors (Å ²)			
Overall	49.8		
Protein	49.8		
Ligand¶	44.3		
Water	38.7		
R.m.s.d., bond lengths (Å)	0.009		
R.m.s.d., bond angles (°)	1.28		
Ramachandran favored (%)	96.8		
Ramachandran allowed (%)	3.2		
PDB code	4tn0		

[†] $R_{\text{merge}} = \sum_{hkl} \sum_i |I_i(hkl) - \langle I(hkl) \rangle| / \sum_{hkl} \sum_i I_i(hkl)$, where $I_i(hkl)$ is the *i*th intensity measurement of reflection *hkl* and $\langle I(hkl) \rangle$ is the average intensity for all reflections. [‡] CC_{1/2} is the correlation coefficient between two random half data sets (Karplus & Diederichs, 2012; Diederichs & Karplus, 2013). [§] $R_{\text{work}}/R_{\text{free}} = \sum_{hkl} ||F_{\text{obs}}| - |F_{\text{calc}}|| / \sum_{hkl} |F_{\text{obs}}|$, where F_{obs} and F_{calc} are the observed and calculated structure factors, respectively. [¶] Includes phosphoryl group and Zn atoms.

employed in the collection of mass spectra. The protein sample was eluted with a 0.5 × 50 mm PLRP-S column (8 μm, 4000 Å; Michrom BioResources) with mobile phases *A* and *B* (acetonitrile:water:formic acid:trifluoroacetic acid; *A* = 2:98:0.1:0.01; *B* = 90:10:0.1:0.01). A linear gradient of 5–65% *B* was used to elute protein in 20 min at a flow rate of 20 μl min⁻¹. Automated acquisition of full-scan MS spectra over the range 450–2000 Da was executed by *Xcalibur* (Thermo Scientific). The acquired convoluted protein spectra were deconvoluted by *ProMass for Xcalibur 2.5.0* (Novatia) to yield the [*M* + *H*]⁺ mass-to-charge values.

2.5. Motility assays

C. jejuni strains were initially grown from freezer stocks on MH agar with 10 μg ml⁻¹ trimethoprim for 48 h at 37°C under

microaerobic conditions (5% O₂, 10% CO₂, 85% N₂). Following the initial growth, the strains were re-streaked and grown under the same conditions. After 16 h, the strains were resuspended from agar plates in MH broth and diluted to an OD₆₀₀ of 0.05, stab-inoculated into semisolid MH motility medium (containing 0.4% agar) and incubated for 24 h at 37°C under microaerobic conditions. Relative motilities were assessed from the diameter of the halos of growth. Experiments were performed in duplicate.

2.6. Polymyxin B resistance assay

Strains were grown in the same manner as described for the motility assays in §2.5 and swabbed onto MH agar plates with 10 μg ml⁻¹ trimethoprim. Polymyxin B Etest strips (bioMérieux) were applied to the swabbed plates and incubated in microaerobic conditions for 48 h at 37°C before reading minimal inhibitory concentrations (MICs). Experiments were performed in duplicate.

3. Results and discussion

3.1. Overall structure of the catalytic domain of EptC

In order to examine the structural basis for enzyme function, we over-expressed the catalytic domain of EptC (cEptC; residues 203–512) fused to a C-terminal Gly₆His₈ tag and determined the X-ray crystal structure (Fig. 2). After testing many gene truncations, we obtained one that expressed sufficient soluble protein suitable for crystallography and confirmed the molecular weight of the gene product (Supplementary Fig. S2). Including the His tag, cEptC is composed of 325 residues and has a molecular weight of 36.7 kDa. The phases of cEptC were elucidated from a SAD data set collected from a SeMet-derivative cEptC crystal that diffracted to 2.80 Å resolution in space group *P*2₁2₁2₁ (Table 3). Molecular replacement was carried out using one monomer from the SeMet derivative as a search model for the native data set. One native crystal diffracted to 2.40 Å resolution in space group *C*222₁. With the exception of residues 213–215 of chains *A* and *C* and residues 212–214 of chain *B*, there is full coverage of the peptide backbone by the electron-density map between the initiating Met202 and Pro512 (preceding the C-terminal His tag). Elevated *B* factors (overall average = 49.8 Å²), particularly for the lower half of

the structure as arranged in Fig. 2, indicate increased mobility in atomic positions: this may be owing to the absence of the N-terminal transmembrane region of the enzyme or to the dearth of crystal contacts in this region of each chain in the asymmetric unit.

The cEptC catalytic domain assumes an $\alpha/\beta/\alpha$ fold with a six-stranded, central β -sheet that is enveloped by a series of 11 α -helices (Fig. 2), imparting an overall hemispherical shape. β -Strands and α -helices are labeled $\beta 1$ – $\beta 8$ and $\alpha 1$ – $\alpha 11$, respectively (Supplementary Fig. S3). The $\alpha/\beta/\alpha$ fold is common to proteins in the alkaline phosphatase superfamily (pfam00245), which includes sulfatases. Enzymes of this family cleave ester bonds such as sulfoester and phosphoester linkages, a reaction that is likely to be required for EptC function. A zinc-binding site, identified by anomalous diffraction, is located on the flat surface of the hemisphere and is fairly exposed to solvent (Supplementary Fig. S4a). As the putative nucleophile Thr266 resides at the N-terminus of $\alpha 2$, a helical dipole may help to stabilize a nucleophilic alkoxide form of its side chain. A phosphoryl group was found attached to Thr266 to form phosphothreonine (Supplementary Fig. S5), which we speculate mimics a pEtN–enzyme intermediate. Consistent with the location of cEptC in the oxidizing environment of the periplasm, three disulfide bonds are present (Fig. 2): between residues Cys262 and Cys272, Cys312 and Cys316, and Cys377 and Cys385. Cys272 is located on the nucleophilic helix, while Cys262 is on the loop extending from the N-terminus of that helix. Cys312 resides on a loop near the nucleophilic Thr266 and, with Cys316, may play a role in properly positioning an active-site loop, as discussed below. In

contrast, the Cys377–Cys385 pair is more distant from the active site.

3.2. Comparison of cEptC with known phospho-form transferase structures

Phospho-form transferase enzymes transfer phospho-form structures such as pEtN and phosphoglycerol to the hydroxyl and phosphoryl groups of target molecules to promote their biological functions. In addition to the cEptC structure presented here, the structures of two other phospho-form transferase proteins have previously been reported: the catalytic domain of *S. aureus* (Lu *et al.*, 2009) and *B. subtilis* (Schirner *et al.*, 2009) lipoteichoic acid synthase LtaS (cLtaS; PDB entries 2w5s and 2w8d), and most recently the catalytic domain of the lipid A pEtN transferase LptA (cLptA; PDB entry 4kay) of *N. meningitidis* (Wanty *et al.*, 2013). LtaS, a phosphoglycerol transferase that is distantly related to EptC, synthesizes the polyphosphoglycerol backbone structure of lipoteichoic acid in Gram-positive bacteria. LptA is functionally similar to EptC in that it adds pEtN to the phosphoryl groups of lipid A; however, LptA displays specificity for lipid A alone, while EptC has multiple molecular targets. Like cEptC, the C-terminal domains cLptA and cLtaS adopt the $\alpha/\beta/\alpha$ alkaline phosphatase-like fold (Fig. 3), which is fused to a predicted N-terminal five-helix transmembrane domain. Together, these three proteins represent a class of bacterial membrane-associated, biosynthetic enzymes with similar activities (phospho-form transfer), although the products and biological outcomes are widely varied.




Figure 3

Overall structures of the pEtN transferases cEptC and cLptA and the *B. subtilis* lipoteichoic acid synthase cLtaS. (a) cEptC (green), with phosphothreonine and disulfides shown in ball-and-stick representation and the Zn^{2+} ion as a purple sphere. (b) cLptA (PDB entry 4kay; cyan), with phosphothreonine and disulfides shown in ball-and-stick representation and Zn^{2+} ions as purple spheres. Structural insertions found in cLptA, but not cEptC, are colored yellow. cLptA and cEptC superpose with a C^α r.m.s.d. of 0.59 Å over 211 residues. (c) *B. subtilis* cLtaS (PDB entry 2w8d; orange), with phosphothreonine shown in ball-and-stick representation and the Mg^{2+} ion as a green sphere. Structural features unique to cLtaS are colored blue. cLtaS and cEptC superpose with a C^α r.m.s.d. of 3.74 Å over 216 residues.

The cEptC and cLtaS structures share a number of common core β -strands and α -helices that align with a C^α r.m.s.d. of 3.74 Å over 216 residues (Figs. 3*a* and 3*c*; Supplementary Figs. S4*a* and S4*c*). The main differences between the two structures are the positioning of the loop regions and the presence of insertions that are only observed in cLtaS. For instance, cLtaS has an extra 79-residue C-terminal region composed of a five-stranded β -sheet and a long α -helix. Additionally, a helix–loop–helix structure spanning residues 477–500 corresponds to a loop region between β_6 and β_7 of cEptC. Interestingly, this loop in the cEptC structure is oriented towards the active site and positions His440 N^{e2} within hydrogen-bonding distance (3.0 Å) of a phosphoryl O atom of phospho-Thr266 (Figs. 3*a* and 4*a*). In contrast, the helix–loop–helix structure of cLtaS is oriented in the opposite direction, causing this region of the active site to be more open in cLtaS (Figs. 3*c* and 4*c*). Finally, LtaS contains an additional helix positioned in a loop region between the corresponding β_2 and β_3 of cEptC (Figs. 4*a* and 4*c*). Side chains on the N-terminal end of this helix and the preceding loop have been shown to bind phosphoglycerol in *S. aureus* cLtaS (PDB entry 2w5s; Lu *et al.*, 2009). The major structural differences observed between cEptC and cLtaS presumably contribute to their distinct enzyme–substrate interactions.

The cEptC and cLptA structures are strikingly similar, as noted by their 44% amino-acid sequence identity and observed C^α r.m.s.d. of 0.59 Å over 211 residues (Figs. 3*a* and 3*b*; Supplementary Figs. S4*a* and S4*b*). The disulfide-bonding pattern of cLptA is identical to that of cEptC, with the exception of two additional disulfides between residues Cys348–Cys353 and Cys499–Cys540 in cLptA. Interestingly, these extra disulfides occur in the only regions that differ significantly from cEptC. Cys499 is part of an α -helix that corresponds to α_{10} of cEptC. Also, cLptA contains an extra eight-residue α -helix between the corresponding β_8 and α_{10} of cEptC that, together with the Cys499–Cys540 disulfide, causes α_{10} to take on a different pitch than observed in cEptC.

The second additional disulfide between Cys348 and Cys353 of cLptA is in a loop spanning residues 339–354 adjacent to the active site. Curiously, this loop is significantly shorter in the cEptC structure (residues 325–329), despite the similarity in sequence and structure to cLptA around this region. It is possible that this extended loop plays a part in substrate specificity in cLptA, and its absence from the cEptC structure may allow the entry of more diverse molecular targets.

3.3. Active-site architecture of cEptC

The cEptC active site contains a tetrahedrally coordinated zinc ion and a putative nucleophilic threonine, Thr266, covalently bound to a phosphoryl group to form phosphothreonine (Fig. 4*a*). We reason that phospho-Thr266 mimics an enzyme reaction intermediate representing the first step in a two-step transferase reaction. Phosphothreonine was also observed in the cLptA (Wanty *et al.*, 2013) and *B. subtilis* cLtaS (Schirner *et al.*, 2009) structures (Figs. 3*b* and 3*c*).

Coordinated divalent metals are important cofactors for enzymes in the alkaline phosphatase protein superfamily, as they are implicated in substrate binding and catalysis (Kim & Wyckoff, 1991; O'Brien & Herschlag, 2001; Stec *et al.*, 2000). The cEptC zinc ion is tetrahedrally coordinated by residues Glu227, phospho-Thr266, Asp427 and His428. By sequence alignment and structural comparison, these residues are highly conserved in the characterized phospho-form transferase members of COG2194 (includes pEtN transferases) and COG1368 (includes phosphoglycerol transferases) (Supplementary Fig. S6). The orientation of these residues is well conserved between cEptC, cLptA and cLtaS, with r.m.s.d. values of 0.26 Å over 30 atoms and 0.18 Å over 21 atoms when comparing cEptC with cLptA and *B. subtilis* cLtaS, respectively (Supplementary Fig. S7). Of the two cLtaS structures solved, one was shown to bind a magnesium ion (Schirner *et al.*, 2009) and the other a manganese ion (Lu *et al.*, 2009) (compare Supplementary Fig. S7*c* and Fig. 4*c*). The cLptA




Figure 4

Juxtaposed active sites of (a) cEptC, (b) cLptA (PDB entry 4kay) and (c) *S. aureus* cLtaS (PDB entry 2w5s). Active-site architectures and zinc-binding residues are conserved between cEptC and cLptA (Supplementary Fig. S6), although only one Zn^{2+} ion associates with cEptC *in crystallo*. His358/His383 and metal-ligand residues of cEptC and cLptA are also conserved in cLtaS. Side chains on an active-site loop/helix of cLtaS, corresponding to a loop between β_2 and β_3 of cEptC, bind phosphoglycerol (PG, white C atoms; Lu *et al.*, 2009). In cEptC and cLptA, this loop contains Asn308/Asp324 and Ser309/Ser325, which may contribute to substrate binding. Notably, Thr266, His358, His440, Asn308 and Ser309 mutant strains of *eptC* in *C. jejuni* displayed polymyxin B sensitivity and a severe loss of motility (Figs. 5 and 6).

structure, on the other hand, contains two zinc ions (Fig. 4*b*), reminiscent of the *E. coli* alkaline phosphatase PhoA (PDB entry 1ed8; Wanty *et al.*, 2013; Stec *et al.*, 2000). It is worth noting that only one zinc ion, corresponding to the zinc and magnesium/manganese ions of cEptC and cLtaS, was observed unless the cLptA crystals were soaked with 1 mM zinc sulfate. Nevertheless, the zinc-coordinating residues of cLptA superimpose well onto corresponding residues of alkaline phosphatase (Wanty *et al.*, 2013) and, importantly, most of these residues are conserved in cEptC, cLtaS and several diverse pEtN transferases (Supplementary Fig. S6). More specifically, the first-zinc ligand residues Glu227/240, Thr266/280, Asp427/452 and His428/453 of cEptC/cLptA directly correspond to Asp51, Ser102, Asp369 and His370 of alkaline phosphatase, and the second-zinc ligand residues His358/383 and His440/465 correspond to Asp327 and His412 of alkaline phosphatase. Another second-zinc ligand residue, His331, is found in alkaline phosphatase but not in cLptA or cEptC. Additional studies will be necessary to determine the extent of this similarity, as well as the capacity of cEptC to bind multiple zinc ions.

3.4. Mutational characterization of conserved cEptC active-site residues

Based on a sequence alignment of COG2194 members (Supplementary Fig. S6), we identified conserved amino-acid residues that correspond to the cEptC active-site residues Thr266, Asn308, Ser309, His358 and His440 (Fig. 4*a*). In order to assess the functional requirement of these active-site residues, we prepared mutant strains of *C. jejuni* 81-176 carrying point mutations for each residue, as described in §2.1. We previously established that a functional *eptC* allele is required for pEtN modification of the flagellar rod protein FlgG and lipid A in *C. jejuni* (Cullen & Trent, 2010; Cullen *et al.*, 2012). These modifications are unequivocally responsible for proper flagellar assembly, motility and resistance to polymyxin B. To this end, we monitored the *in vivo* activity of mutant EptC enzymes by comparing the minimal inhibitory concentration (MIC) of polymyxin B and the halo-of-growth diameter in motility assays. All of the active-site mutants were significantly less resistant to polymyxin B when compared with the parent strain 81-176 (Fig. 5). The S309A mutant displayed a sixfold decrease in polymyxin B resistance, while the remaining active-site mutants and the $\Delta eptC$ null mutant displayed a 15.8-fold decrease. All of the mutants were also significantly impaired with respect to motility (Fig. 6). Interestingly, the N308A, S309A, H440A, H358A and T266S mutants displayed the most severe motility defects, while the T266A mutant was comparable to the $\Delta eptC$ null strain after 24 h of growth. It was previously determined that roughly 10% of the $\Delta eptC$ mutant population produces visible flagella (Cullen & Trent, 2010), giving rise to partial recovery of motility as demonstrated in Fig. 6 (compare 81-176, $\Delta eptC$ and the nonmotile strain H358A as a reference). The more pronounced motility defects observed for most of the active-site mutants presented here may reflect the fact that these strains express inactive

protein that precludes partial recovery of motility *via* unknown mechanisms.

Taken together, the loss of motility and polymyxin B resistance suggest a crucial role for Thr266, Asn308, Ser309, His358 and His440 in EptC function. Notably, Asn308 O^{δ1}, Asn308 N^{δ2} and Ser309 O^γ are 5.5, 6.7 and 6.4 Å from phospho-Thr266 O3P (chain A), respectively, which places




Figure 5 Minimal inhibitory concentrations (MICs) of polymyxin B for *C. jejuni* EptC active-site mutants. Parent strain (81-176), *eptC* null mutant ($\Delta eptC$), complemented $\Delta eptC$ strain carrying a copy of the native *eptC* allele ($\Delta eptC/eptC^+$) and mutant strains carrying *eptC* alleles with single amino-acid mutations (T266A, T266S, N308A, S309A, H358A and H440A) were swabbed onto MH agar plates with 10 µg ml⁻¹ trimethoprim and subjected to the polymyxin B Etest strip assay. MICs were recorded after 48 h. The numbers above each bar in the graph indicate polymyxin B MICs in µg ml⁻¹.




Figure 6 EptC active-site mutant motility assays. Parent strain (81-176), *eptC* null mutant ($\Delta eptC$), complemented $\Delta eptC$ strain ($\Delta eptC/eptC^+$) and strains carrying *eptC* active-site mutant alleles (T266A, T266S, N308A, S309A, H358A and H440A) were stab-inoculated into semisolid MH motility medium and incubated under microaerobic conditions. To assess relative motility, bacterial growth diameters were visually compared 24 h post-inoculation.

them within hydrogen-bonding distance of a pEtN moiety covalently linked to Thr266.

To further explore the phosphorylation of Thr266, we expressed and purified soluble cEptC protein that contained a T266S mutation and investigated the presence of phosphoserine. The molecular weights of native and mutant cEptC proteins were determined by mass spectrometry in the positive mode with an accuracy of ± 5 u. The deconvoluted cEptC spectrum showed a major peak at 36 750 u, consistent with the calculated $[M + H]^+$ of native cEptC (Supplementary Fig. S2a). As expected, another major peak was observed with a mass shift of +80 u, demonstrating the presence of phosphothreonine as observed in the cEptC crystal structure. Corresponding peaks with masses of 36 477 and 36 556 u suggest the loss of two histidine residues (-273 u), likely owing to proteolysis of the disordered His tag during expression and purification. In contrast to native cEptC, the T266S mutant spectrum showed one major peak at 36 740 u, consistent with unmodified protein, and a corresponding minor peak indicating the loss of two histidine residues (-272 u; Supplementary Fig. S2c). Taken together, these results suggest that serine cannot replace threonine in EptC catalysis and that the phosphothreonine observed in the cEptC crystal structure and mass spectrum is indeed most likely owing to the catalytic activity of cEptC.

4. Conclusion

We present the structure of the catalytic domain of EptC, the only known phosphoethanolamine transferase from the Gram-negative pathogen *C. jejuni*. Despite the wide array of molecules modified by EptC, our structure displays extensive similarities to the lipid A-specific cLptA of *N. meningitidis* and fewer similarities to the distantly related phosphoglycerol-specific cLtaS of *B. subtilis* and *S. aureus*. Like cLptA and cLtaS, cEptC assumes an $\alpha/\beta/\alpha$ fold that coordinates a divalent metal ion and possesses a nucleophilic threonine modified with a phosphoryl group. We suggest that this residue mimics a covalent phosphoethanolamine–enzyme intermediate. Given the similarities among the active sites of these phosphoform transferases and alkaline phosphatase, the enzymes are expected to share mechanistic features. *C. jejuni* strains with point mutations at EptC residues Thr266, Asn308, Ser309, His358 and His440 suffered polymyxin B sensitivity and severe loss of motility, indicating that the active sites of EptC and other lipid A phosphoethanolamine transferases may be effective targets for drug design. *C. jejuni* has increasingly been recognized as a major causative agent of foodborne illness worldwide. Our analysis of the catalytic domain of EptC augments the structural characterization of phosphoethanolamine transferases and sets the foundation for the development of inhibitory drugs to combat infections by *C. jejuni* and related bacteria.

5. Related literature

The following references are cited in the Supporting Information for this article: Laskowski (2009) and Sievers & Higgins (2014).

This work was supported by the National Institutes of Health (grants AI064184 and AI076322 to MST and grant GM106112 to ATK) and the Army Research Office (grant W911NF-12-1-0390 to MST). Instrumentation and technical assistance for this work were provided by the Macromolecular Crystallography Facility, with financial support from the College of Natural Sciences, the Office of the Executive Vice President and Provost, and the Institute for Cellular and Molecular Biology at the University of Texas at Austin. Use of the Advanced Photon Source, an Office of Science User Facility operated for the US Department of Energy (DOE) Office of Science by Argonne National Laboratory, was supported by the US DOE under Contract No. DE-AC02-06CH11357. The Berkeley Center for Structural Biology is supported in part by the National Institutes of Health, National Institute of General Medical Sciences and the Howard Hughes Medical Institute. The Advanced Light Source is supported by the Director, Office of Science, Office of Basic Energy Sciences of the US Department of Energy under Contract No. DE-AC02-05CH11231. We thank Maria Person and the Proteomics Facility at the University of Texas at Austin and funding sources ES007784 (CRED) and RP110782 (CPRIT) for producing protein mass-spectrometry data. We also thank Jay Nix for assistance with anomalous data collection and processing.

References

- Adams, P. D. *et al.* (2010). *Acta Cryst.* **D66**, 213–221.
 Batz, M. B., Hoffmann, S. & Morris, J. G. Jr (2012). *J. Food Prot.* **75**, 1278–1291.
 Burmeister, W. P. (2000). *Acta Cryst.* **D56**, 328–341.
 Chamot-Rooke, J., Mikaty, G., Malosse, C., Soyer, M., Dumont, A., Gault, J., Imhaus, A. F., Martin, P., Trellet, M., Clary, G., Chafey, P., Camoin, L., Nilges, M., Nassif, X. & Duménil, G. (2011). *Science*, **331**, 778–782.
 Chevance, F. F. & Hughes, K. T. (2008). *Nature Rev. Microbiol.* **6**, 455–465.
 Cox, A. D., Wright, J. C., Li, J., Hood, D. W., Moxon, E. R. & Richards, J. C. (2003). *J. Bacteriol.* **185**, 3270–3277.
 Cullen, T. W., Madsen, J. A., Ivanov, P. L., Brodbelt, J. S. & Trent, M. S. (2012). *J. Biol. Chem.* **287**, 3326–3336.
 Cullen, T. W., O'Brien, J. P., Hendrixson, D. R., Giles, D. K., Hobb, R. I., Thompson, S. A., Brodbelt, J. S. & Trent, M. S. (2013). *Infect. Immun.* **81**, 430–440.
 Cullen, T. W. & Trent, M. S. (2010). *Proc. Natl Acad. Sci. USA*, **107**, 5160–5165.
 Diederichs, K. & Karplus, P. A. (2013). *Acta Cryst.* **D69**, 1215–1222.
 Doublé, S. (1997). *Methods Enzymol.* **276**, 523–530.
 Emsley, P. & Cowtan, K. (2004). *Acta Cryst.* **D60**, 2126–2132.
 Evans, P. (2006). *Acta Cryst.* **D62**, 72–82.
 French, S. & Wilson, K. (1978). *Acta Cryst.* **A34**, 517–525.
 Havelaar, A. H., Ivarsson, S., Löfdahl, M. & Nauta, M. J. (2013). *Epidemiol. Infect.* **141**, 293–302.
 Israeli, E., Agmon-Levin, N., Blank, M., Chapman, J. & Shoenfeld, Y. (2012). *Clin. Rev. Allergy Immunol.* **42**, 121–130.
 Kabsch, W. (2010). *Acta Cryst.* **D66**, 125–132.
 Karplus, P. A. & Diederichs, K. (2012). *Science*, **336**, 1030–1033.
 Kim, E. E. & Wyckoff, H. W. (1991). *J. Mol. Biol.* **218**, 449–464.
 Klock, H. E. & Lesley, S. A. (2009). *Methods Mol. Biol.* **498**, 91–103.
 Laskowski, R. A. (2009). *Nucleic Acids Res.* **37**, D355–D359.
 Lu, D., Wörmann, M. E., Zhang, X., Schneewind, O., Gründling, A. & Freemont, P. S. (2009). *Proc. Natl Acad. Sci. USA*, **106**, 1584–1589.

- Mackinnon, F. G., Cox, A. D., Plested, J. S., Tang, C. M., Makepeace, K., Coull, P. A., Wright, J. C., Chalmers, R., Hood, D. W., Richards, J. C. & Moxon, E. R. (2002). *Mol. Microbiol.* **43**, 931–943.
- Marchler-Bauer, A. *et al.* (2013). *Nucleic Acids Res.* **41**, D348–D352.
- McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C. & Read, R. J. (2007). *J. Appl. Cryst.* **40**, 658–674.
- Murshudov, G. N., Skubák, P., Lebedev, A. A., Pannu, N. S., Steiner, R. A., Nicholls, R. A., Winn, M. D., Long, F. & Vagin, A. A. (2011). *Acta Cryst.* **D67**, 355–367.
- Naessan, C. L., Egge-Jacobsen, W., Heiniger, R. W., Wolfgang, M. C., Aas, F. E., Røhr, A., Winther-Larsen, H. C. & Koomey, M. (2008). *J. Bacteriol.* **190**, 387–400.
- Needham, B. D. & Trent, M. S. (2013). *Nature Rev. Microbiol.* **11**, 467–481.
- O'Brien, P. J. & Herschlag, D. (2001). *Biochemistry*, **40**, 5691–5699.
- Otwinowski, Z. & Minor, W. (1997). *Methods Enzymol.* **276**, 307–326.
- Raetz, C. R. H., Reynolds, C. M., Trent, M. S. & Bishop, R. E. (2007). *Annu. Rev. Biochem.* **76**, 295–329.
- Read, R. J. & Schierbeek, A. J. (1988). *J. Appl. Cryst.* **21**, 490–495.
- Scallan, E., Hoekstra, R. M., Angulo, F. J., Tauxe, R. V., Widdowson, M. A., Roy, S. L., Jones, J. L. & Griffin, P. M. (2011). *Emerg. Infect. Dis.* **17**, 7–15.
- Schirner, K., Marles-Wright, J., Lewis, R. J. & Errington, J. (2009). *EMBO J.* **28**, 830–842.
- Scott, N. E., Nothaft, H., Edwards, A. V. G., Labbate, M., Djordjevic, S. P., Larsen, M. R., Szymanski, C. M. & Cordwell, S. J. (2012). *J. Biol. Chem.* **287**, 29384–29396.
- Sievers, F. & Higgins, D. G. (2014). *Methods Mol. Biol.* **1079**, 105–116.
- Stec, B., Holtz, K. M. & Kantrowitz, E. R. (2000). *J. Mol. Biol.* **299**, 1303–1311.
- Trent, M. S., Stead, C. M., Tran, A. X. & Hankins, J. V. (2006). *J. Endotoxin Res.* **12**, 205–223.
- Wanty, C., Anandan, A., Piek, S., Walshe, J., Ganguly, J., Carlson, R. W., Stubbs, K. A., Kahler, C. M. & Vrielink, A. (2013). *J. Mol. Biol.* **425**, 3389–3402.
- Weik, M., Ravelli, R. B. G., Kryger, G., McSweeney, S., Raves, M. L., Harel, M., Gros, P., Silman, I., Kroon, J. & Sussman, J. L. (2000). *Proc. Natl Acad. Sci. USA*, **97**, 623–628.
- Wenzel, C. Q., St Michael, F., Stupak, J., Li, J., Cox, A. D. & Richards, J. C. (2010). *J. Bacteriol.* **192**, 208–216.
- Winn, M. D. *et al.* (2011). *Acta Cryst.* **D67**, 235–242.
- Wright, J. C., Hood, D. W., Randle, G. A., Makepeace, K., Cox, A. D., Li, J., Chalmers, R., Richards, J. C. & Moxon, E. R. (2004). *J. Bacteriol.* **186**, 6970–6982.
- Yuki, N. & Hartung, H. P. (2012). *N. Engl. J. Med.* **366**, 2294–2304.